Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 3/20 | 0.66 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.66 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.66 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.66 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.66 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.66 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.55 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Profadol SCHEMBL122313 | 0.99 | ACHE (0.64) | ACHEOPRM1SLC22A1CHRM2SLC6A4 | |
| SCHEMBL542062 | 0.80 | ACHE (0.77) | ACHEOPRM1SLC22A1CHRM2SLC6A4 | |
| Meptazinol SCHEMBL25404 | 0.80 | ACHE (1.00) | ACHEOPRM1SLC22A1CHRM2SLC6A4 | |
| Meptazinol SCHEMBL12125416 | 0.80 | ACHE (1.00) | ACHEOPRM1SLC22A1CHRM2SLC6A4 | |
| Meptazinol SCHEMBL11947491 | 0.80 | ACHE (1.00) | ACHEOPRM1SLC22A1CHRM2SLC6A4 | |
| SCHEMBL11635885 | 0.79 | ACHE (0.56) | ACHEOPRM1SLC22A1CHRM2SLC6A4 | |
| SCHEMBL6654583 | 0.79 | DRD3 (0.66) | ACHEOPRM1 | |
| Meptazinol SCHEMBL542305 | 0.78 | ACHE (0.97) | ACHEOPRM1SLC22A1CHRM2SLC6A4 | |
| Meptazinol SCHEMBL124401 | 0.78 | ACHE (0.97) | ACHEOPRM1SLC22A1CHRM2SLC6A4 | |
| Meptazinol SCHEMBL1651915 | 0.77 | ACHE (0.95) | ACHEOPRM1SLC22A1CHRM2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1270 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12133922-B2 | Abuse resistant capsule | R.P. SCHERER TECHNOLOGIES, LLC (US) | 2024-11-05 | — | — | US | claimed |
| US-20220362160-A1 | ABUSE RESISTANT CAPSULE | R.P. SCHERER TECHNOLOGIES, LLC (US) | 2022-11-17 | — | — | US | claimed |
| US-11464747-B2 | Abuse resistant capsule | R.P. SCHERER TECHNOLOGIES, LLC (US) | 2022-10-11 | — | — | US | claimed |
| US-11052082-B2 | Combination of opioids and anticancer drugs for cancer treatment | UNIVERSITÄT ULM (DE) | 2021-07-06 | — | — | US | claimed |
| EP-3446681-B1 | ABUSE RESISTANT CAPSULE | SCHERER TECHNOLOGIES LLC R P (US) | 2020-12-23 | — | — | EP | claimed |
| US-10744131-B2 | Abuse-resistant drug formulations | KASHIV BIOSCIENCES, LLC (US) | 2020-08-18 | — | — | US | claimed |
| CN-104271114-B | Oral film containing opiate enteric release beads | LTS勒曼治疗系统股份公司 | 2019-12-03 | — | — | CN | claimed |
| US-10420729-B2 | Abuse resistant capsule | R.P. SCHERER TECHNOLOGIES, LLC (US) | 2019-09-24 | — | — | US | claimed |
| CN-110227161-A | CNS inhibitor is combined with opioid for the purposes in endoscopy | 江苏恒瑞医药股份有限公司 | 2019-09-13 | — | — | CN | claimed |
| US-10377779-B2 | Carbonate prodrugs and methods of using the same | ACORDA THERAPEUTICS, INC. (US) | 2019-08-13 | — | — | US | claimed |
| US-5618803-A | TO BRAIN | UNIVERSITY OF FLORIDA (US) | 1997-04-08 | — | — | US | claimed |
| EP-0760661-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING AN OPIATE ANTAGONIST AND CALCIUM SALTS, THEIR USE FOR THE TREATMENT OF ENDORPHIN-MEDIATED PATHOLOGIES | Minoia, Paolo (IT) | 1997-03-12 | — | — | EP | claimed |
| WO-1995031985-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING AN OPIATE ANTAGONIST AND CALCIUM SALTS, THEIR USE FOR THE TREATMENT OF ENDORPHIN-MEDIATED PATHOLOGIES | MINOIA PAOLO (IT) | 1995-11-30 | — | — | WO | claimed |
| EP-0290482-B1 | TRANSDERMAL ABSORPTION DOSAGE UNIT FOR NARCOTIC ANALGESICS AND ANTAGONISTS AND PROCESS FOR ADMINISTRATION | UNIV RUTGERS (US) | 1995-03-08 | — | — | EP | claimed |
| US-4806341-A | BACKING LAYER, POLYMER MATRIX DISC WITH DRUG MICRODISPERSED THEREIN | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 1989-02-21 | — | — | US | claimed |
| EP-0046270-B1 | NOVEL DERIVATIVES OF BIO-AFFECTING PHENOLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITION CONTAINING THEM | INTERx RESEARCH CORPORATION (US) | 1986-05-21 | — | — | EP | claimed |
| EP-0152379-A2 | Process for preparing pharmaceutical compositions containing unilamellar liposomes | CIBA-GEIGY AG (CH) | 1985-08-21 | — | — | EP | claimed |
| EP-0077393-A1 | NOVEL METHOD OF ADMINISTERING NARCOTIC ANTAGONISTS AND ANALGESICS AND NOVEL DOSAGE FORMS CONTAINING SAME | The University of Kentucky Research Foundation (US) | 1983-04-27 | — | — | EP | claimed |
| WO-1982003768-A1 | NOVEL METHOD OF ADMINISTERING NARCOTIC ANTAGONISTS AND ANALGESICS AND NOVEL DOSAGE FORMS CONTAINING SAME | UNIV KENTUCKY (US) | 1982-11-11 | — | — | WO | claimed |
| EP-0046270-A1 | Novel derivatives of bio-affecting phenolic compounds and pharmaceutical composition containing them | INTERx RESEARCH CORPORATION (US) | 1982-02-24 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11052082-B2 | Combination of opioids and anticancer drugs for cancer treatment | OPRM1, OPRL1, OPRK1 | ACHE 2965/4885OPRM1 1/4885SLC22A1 1025/4885 |
| US-10377779-B2 | Carbonate prodrugs and methods of using the same | CA6, CA7, CA4 | ACHE 1553/4885OPRM1 2263/4885SLC22A1 417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.